SDEV— Stablecoin Development Corp

MaterialsPharmaceuticals$52M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
General and administrative	$7.6M+2.8%	$7.4M+35.5%	$5.4M-27.3%	$7.5M
Impairment of long-lived assets	$854K	$0	—	—
Total operating expenses	$8.4M+14.4%	$7.4M-27.6%	$10.2M-54.1%	$22.2M
Operating loss	-$8.4M-14.4%	-$7.4M-79.9%	-$4.1M+71.5%	-$14.4M
Non-cash (loss) gain on changes in fair value of warrant liability	-$24.5M-21578.9%	$114K-58.1%	$272K-95.0%	$5.4M
Accretion of interest and amortization of discounts on convertible notes	-$277K+69.4%	-$904K+46.6%	-$1.7M	—
Other expense, net	-$20K+96.6%	-$581K-57.5%	-$369K-33.7%	-$276K
Net loss from continuing operations	-$33.2M-279.7%	-$8.8M-42.4%	-$6.1M	—
Net income from discontinued operations, net of taxes	$11.1M+625.7%	$1.5M+139.2%	-$3.9M	—
Net loss	-$22.1M-206.5%	-$7.2M+25.1%	-$9.6M+9.1%	-$10.6M
Less: Increase to accumulated deficit due to adjustment to common stock warrant exercise price	$0+100.0%	-$1.0M	$0	—
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price	$0+100.0%	-$380K+94.6%	-$7.1M-224.7%	$5.7M
Net loss attributable to common stockholders	-$22.1M-157.2%	-$8.6M+49.3%	-$17.0M-4.3%	-$16.3M
Basic (and diluted for net loss) (in shares)	5.8M+757.1%	679K+465.8%	120K+7353.4%	2K
Basic loss per share from continuing operations (in dollars per share)	-$5700.00+61.8%	-$14930.00+86.4%	-$110020.00	—
Basic earnings per share from discontinued operations (in dollars per share)	$1900.00-15.6%	$2250.00+107.7%	-$29120.00	—
Basic (loss) earnings per share attributable to common stockholders (in dollars per share)	-$3800.00+70.0%	-$12680.00+90.9%	-$139140.00-1377523.8%	-$10.10

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.